Antibody-independent, interleukin-17A-mediated, cross-serotype immunity to pneumococci in mice immunized intranasally with the cell wall polysaccharide

Infection and Immunity

Volumn 74, Issue 4, 2006, Pages 2187-2195

  Malley, Richard ^a   Srivastava, Amit ^a   Lipsitch, Marc ^b   Thompson, Claudette M ^b   Watkins, Claire ^a   Tzianabos, Arthur ^c   Anderson, Porter W ^d  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOLYTE; BACTERIAL POLYSACCHARIDE; INTERLEUKIN 17; INTERLEUKIN 17A; UNCLASSIFIED DRUG;

ACETYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; ASPIRATION PNEUMONIA; BACTERIAL COLONIZATION; CONTROLLED STUDY; MOUSE; NASOPHARYNX; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN MOTIF; STREPTOCOCCUS PNEUMONIAE; T LYMPHOCYTE ACTIVATION;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; CD4-POSITIVE T-LYMPHOCYTES; CELL WALL; IMMUNOGLOBULIN G; INTERLEUKIN-17; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, NUDE; NASOPHARYNGEAL DISEASES; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; POLYSACCHARIDES, BACTERIAL; PROTEIN SUBUNITS; SEROTYPING; STREPTOCOCCUS PNEUMONIAE;

EID: 33645521806     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.74.4.2187-2195.2006     Document Type: Article

References (60)

1. Au, C. C., and T. K. Eisenstein. 1981. Nature of the cross-protective antigen in subcellular vaccines of Streptococcus pneumoniae. Infect. Immun. 31:160-168.
2. Balachandran, P., A. Brooks-Walter, A. Virolainen-Julkunen, S. K. Hollingshead, and D. E. Briles. 2002. Role of pneumococcal surface protein C in nasopharyngeal carriage and pneumonia and its ability to elicit protection against carriage of Streptococcus pneumonias. Infect. Immun. 70:2526-2534.
3. Berry, A. M., and J. C. Paton. 1996. Sequence heterogeneity of PsaA, a 37-kilodalton putative adhesin essential for virulence of Streptococcus pneumoniae. Infect. Immun. 64:5255-5262.
4. Black, S., H. Shinefield, B. Fireman, E. Lewis, P. Ray, J. R. Hansen, L. Elvin, K. M. Ensor, J. Hackell, G. Siber, F. Malinoski, D. Madore, I. Chang, R. Kohberger, W. Watson, R. Austrian, K. Edwards, and the Northern California Kaiser Permanente Vaccine Study Center Group. 2000. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr. Infect. Dis. J. 19:187-195.
5. Bornstein, D. L., G. Schiffman, H. P. Bernheimer, and R. Austrian. 1968. Capsulation of pneumococcus with soluble C-like (Cs) polysaccharide. I. Biological and genetic properties of Cs pneumococcal strains. J. Exp. Med. 128:1385-1400.
6. Briles, D. E., S. Hollingshead, A. Brooks-Walter, G. S. Nabors, L. Ferguson, M. Schilling, S. Gravenstein, P. Braun, J. King, and A. Swift. 2000. The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection. Vaccine 18:1707-1711.
7. Briles, D. E., S. K. Hollingshead, J. C. Paton, E. W. Ades, L. Novak, F. W. van Ginkel, and W. H. Benjamin, Jr. 2003. Immunizations with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniae. J. Infect. Dis. 188:339-348.
8. Briles, D. E., M. Nahm, K. Schroer, J. Davie, P. Baker, J. Kearney, and R. Barletta. 1981. Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 Streptococcus pneumoniae. J. Exp. Med. 153:694-705.
9. Brundish, D. E., and J. Baddiley. 1968. Pneumococcal C-substance, a ribitol teichoic acid containing choline phosphate. Biochem. J. 110:573-582.
10. + T cells mediate abscess formation in intra-abdominal sepsis by an IL-17-dependent mechanism. J. Immunol. 170:1958-1963.
11. Cobb, B. A., Q. Wang, A. O. Tzianabos, and D. L. Kasper. 2004. Polysaccharide processing and presentation by the MHCII pathway. Cell 117:677-687.
12. Dagan, R., R. Melamed, M. Muallem, L. Piglansky, D. Greenberg, O. Abramson, P. M. Mendelman, N. Bohidar, and P. Yagupsky. 1996. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J. Infect. Dis. 174:1271-1278.
13. Fischer, W. 2000. Pneumococcal lipoteichoic and teichoic acid. In A. Tomasz (ed.), Streptococcus pneumoniae: molecular biology & mechanisms of disease. Mary Ann Liebert, Larchmont, N.Y.
14. Goldenberg, H. B., T. L. McCool, and J. N. Weiser. 2004. Cross-reactivity of human immunoglobulin G2 recognizing phosphorylcholine and evidence for protection against major bacterial pathogens of the human respiratory tract. J. Infect. Dis. 190:1254-1263.
15. Gould, J. M., and J. N. Weiser. 2002. The inhibitory effect of C-reactive protein on bacterial phosphorylcholine platelet-activating factor receptor-mediated adherence is blocked by surfactant. J. Infect. Dis. 186:361-371.
16. Grusby, M. J., H. Auchincloss, Jr., R. Lee, R. S. Johnson, J. P. Spencer, M. Zijlstra, R. Jaenisch, V. E. Papaioannou, and L. H. Glimcher. 1993. Mice lacking major histocompatibility complex class I and class II molecules. Proc. Natl. Acad. Sci. USA 90:3913-3917.
17. Han, S. H., J. H. Kim, M. Martin, S. M. Michalek, and M. H. Nahm. 2003. Pneumococcal lipoteichoic acid (LTA) is not as potent as staphylococcal LTA in stimulating Toll-like receptor 2. Infect. Immun. 71:5541-5548.
18. Haneberg, B., and J. Holst. 2002. Can nonliving nasal vaccines be made to work? Expert Rev. Vaccines 1:227-232.
19. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 6:1123-1132.
20. Janeway, C. A., P. Travers, M. Walport, and M. J. Shlomchik. 2001. Immunobiology. Garland Publishing, New York, N.Y.
21. Kadioglu, A., W. Coward, M. J. Colston, C. R. Hewitt, and P. W. Andrew. 2004. CD4-T-lymphocyte interactions with pneumolysin and pneumococci suggest a crucial protective role in the host response to pneumococcal infection. Infect. Immun. 72:2689-2697.
22. Kao, C. Y., Y. Chen, P. Thai, S. Wachi, F. Huang, C. Kim, R. W. Harper, and R. Wu. 2004. IL-17 markedly up-regulates beta-defensin-2 expression in human airway epithelium via JAK and NF-κB signaling pathways. J. Immunol. 173:3482-3491.
23. Kao, C. Y., F. Huang, Y. Chen, P. Thai, S. Wachi, C. Kim, L. Tam, and R. Wu. 2005. Up-regulation of CC chemokine ligand 20 expression in human airway epithelium by IL-17 through a JAK-independent but MEK/NF-κB-dependent signaling pathway. J. Immunol. 175:6676-6685.
24. Kaplan, S. L., E. O. Mason, Jr., E. R. Wald, G. E. Schutze, J. S. Bradley, T. Q. Tan, J. A. Hoffman, L. B. Givner, R. Yogev, and W. J. Barson. 2004. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics 113:443-449.
25. Karlsson, C., P. E. Jansson, and U. B. Skov Sorensen. 1999. The pneumococcal common antigen C-polysaccharide occurs in different forms. Monosubstituted or di-substituted with phosphocholine. Eur. J. Biochem. 265:1091-1097.
26. Kim, J. O., and J. N. Weiser. 1998. Association of intrastrain phase variation in quantity of capsular polysaccharidc and teichoic acid with the virulence of Streptococcus pneumoniae. J. Infect. Dis. 177:368-377.
27. Kitamura, D., J. Roes, R. Kuhn, and K. Rajewsky. 1991. A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. Nature 350:423-426.
28. Kolls, J. K., and A. Linden. 2004. Interleukin-17 family members and inflammation. Immunity 21:467-476.
29. Laferriere, C. A., R. K. Sood, J. M. de Muys, F. Michon, and H. J. Jennings. 1997. The synthesis of Streptococcus pneumoniae polysaccharide-tetanus toxoid conjugates and the effect of chain length on immunogenicity. Vaccine 15:179-186.
30. Lexau, C. A., R. Lynfield, R. Danila, T. Pilishvili, R. Facklam, M. M. Farley, L. H. Harrison, W. Schaffner, A. Reingold, N. M. Bennett, J. Hadler, P. R. Cieslak, and C. G. Whitney. 2005. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 294:2043-2051.
31. Lipsitch, M., C. G. Whitney, E. Zell, T. Kaijalainen, R. Dagan, and R. Malley. 2005. Age-specific incidence of invasive pneumococcal disease by serotype: are anticapsular antibodies the primary mechanism of protection against invasive disease? PLOS Med. 2:e15.
32. Malley, R., M. Lipsitch, A. Stack, R. Saladino, G. Fleisher, S. Pelton, C. Thompson, D. E. Briles, and P. Anderson. 2001. Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by encapsulated pneumococci. Infect. Immun. 69:4870-4873.
33. Malley, R., S. C. Morse, L. C. C. Leite, A. P. Mattos Areas, P. L. Ho, F. S. Kubrusly, I. C. Almeida, and P. Anderson. 2004. Multiserotype protection of mice against pneumococcal colonization of the nasopharynx and middle ear by killed nonencapsulated cells given intranasally with a nontoxic adjuvant. Infect. Immun. 72:4290-4292.
34. + T cells mediate antibody-independent acquired immunity to pneumococcal colonization. Proc. Natl. Acad. Sci. USA 102:4848-4853.
35. McCool, T. L., T. R. Cate, G. Moy, and J. N. Weiser. 2002. The immune response to pneumococcal proteins during experimental human carriage. J. Exp. Med. 195:359-365.
36. McCool, T. L., and J. N. Weiser. 2004. Limited role of antibody in clearance of Streptococcus pneumoniae in a murine model of colonization. Infect. Immun. 72:5807-5813.
37. Miyamoto, M., O. Prause, M. Sjostrand, M. Laan, J. Lotvall, and A. Linden. 2003. Endogenous IL-17 as a mediator of neutrophil recruitment caused by endotoxin exposure in mouse airways. J. Immunol. 170:4665-4672.
38. Musher, D. M., D. A. Watson, and R. E. Baughn. 1990. Does naturally acquired IgG antibody to cell wall polysaccharide protect human subjects against pneumococcal infection? J. Infect. Dis. 161:736-740.
39. Nielsen, S. V., U. B. Sorensen, and J. Henrichsen. 1993. Antibodies against pneumococcal C-polysaccharide are not protective. Microb. Pathog. 14:299-305.
40. Oftung, F., L. M. Naess, L. M. Wetzler, G. E. Korsvold, A. Aase, E. A. Hoiby, R. Dalseg, J. Holst, T. E. Michaelsen, and B. Haneberg. 1999. Antigen-specific T-cell responses in humans after intranasal immunization with a meningococcal serogroup B outer membrane vesicle vaccine. Infect. Immun. 67:921-927.
41. Orihuela, C. J., G. Gao, K. P. Francis, J. Yu, and E. I. Tuomanen. 2004. Tissue-specific contributions of pneumococcal virulence factors to pathogenesis. J. Infect. Dis. 190:1661-1669.
42. Orihuela, C. J., J. N. Radin, J. E. Sublett, G. Gao, D. Kaushal, and E. I. Tuomanen. 2004. Microarray analysis of pneumococcal gene expression during invasive disease. Infect. Immun. 72:5582-5596.
43. Park, H., Z. Li, X. O. Yang, S. H. Chang, R. Nurieva, Y. H. Wang, Y. Wang, L. Hood, Z. Zhu, Q. Tian, and C. Dong. 2005. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6:1133-1141.
44. Schroder, N. W., S. Morath, C. Alexander, L. Hamann, T. Hartung, U. Zahringer, U. B. Gobel, J. R. Weber, and R. R. Schumann. 2003. Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccharide-binding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved. J. Biol. Chem. 278:15587-15594.
45. Skov Sorensen, U. B., J. Blom, A. Birch-Andersen, and J. Henrichsen. 1988. Ultrastructural localization of capsules, cell wall polysaccharide, cell wall proteins, and F antigen in pneumococci. Infect. Immun. 56:1890-1896.
46. Sorensen, U. B., and J. Henrichsen. 1987. Cross-reactions between pneumococci and other streptococci due to C polysaccharide and F antigen. J. Clin. Microbiol. 25:1854-1859.
47. Szu, S. C., R. Schneerson, and J. B. Robbins. 1986. Rabbit antibodies to the cell wall polysaccharide of Streptococcus pneumoniae fail to protect mice from lethal challenge with encapsulated pneumococci. Infect. Immun. 54:448-455.
48. Trolle, S., E. Chachaty, N. Kassis-Chikhani, C. Wang, E. Fattal, P. Couvreur, B. Diamond, J. Alonso, and A. Andremont. 2000. Intranasal immunization with protein-linked phosphorylcholine protects mice against a lethal intranasal challenge with Streptococcus pneumoniae. Vaccine 18:2991-2998.
49. Tuomanen, E. 2004. The pneumococcus. ASM Press, Washington, D.C.
50. Tuomanen, E. I., R. Austrian, and H. R. Masure. 1995. Pathogenesis of pneumococcal infection. N. Engl. J. Med. 332:1280-1284.
51. Tzianabos, A. O., R. W. Finberg, Y. Wang, M. Chan, A. B. Onderdonk, H. J. Jennings, and D. L. Kasper. 2000. T cells activated hy zwitterionic molecules prevent abscesses induced by pathogenic bacteria. J. Biol. Chem. 275:6733-6740.
52. Tzianabos, A. O., A. B. Onderdonk, R. S. Smith, and D. L. Kasper. 1994. Structure-function relationships for polysaccharide-induced intra-abdominal abscesses. Infect. Immun. 62:3590-3593.
53. Wallick, S., J. L. Claflin, and D. E. Briles. 1983. Resistance to Streptococcus pneumoniae is induced by a phosphocholine-protein conjugate. J. Immunol. 130:2871-2875.
54. Weiser, J. N. 1998. Phase variation in colony opacity by Streptococcus pneumoniae. Microb. Drug Resist. 4:129-135.
55. Weiser, J. N., R. Austrian, P. K. Sreenivasan, and H. R. Masure. 1994. Phase variation in pneumococcal opacity: relationship between colonial morphology and nasopharyngeal colonization. Infect. Immun. 62:2582-2589.
56. Wizemann, T. M., J. H. Heinrichs, J. E. Adamou, A. L. Erwin, C. Kunsch, G. H. Choi, S. C. Barash, C. A. Rosen, H. R. Masure, E. Tuomanen, A. Gayle, Y. A. Brewah, W. Walsh, P. Barren, R. Lathigra, M. Hanson, S. Langermann, S. Johnson, and S. Koenig. 2001. Use of a whole-genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. Infect. Immun. 69:1593-1598.
57. World Health Organization. 1999. Pneumococcal vaccines. WHO position paper. Wkly. Epidemiol. Rec. 74:177-183.
58. Yang, S., R. Tamai, S. Akashi, O. Takeuchi, S. Akira, S. Sugawara, and H. Takada. 2001. Synergistic effect of muramyldipeptide with lipopolysaccharide or lipoteichoic acid to induce inflammatory cytokines in human monocytic cells in culture. Infect. Immun. 69:2045-2053.
59. Ye, P., P. B. Garvey, P. Zhang, S. Nelson, G. Bagby, W. R. Summer, P. Schwarzenherger, J. E. Shellito, and J. K. Kolls. 2001. Interleukin-17 and lung host defense against Klebsiella pneumoniae infection. Am. J. Respir. Cell Mol. Biol. 25:335-340.
60. Ye, P., F. H. Rodriguez, S. Kanaly, K. L. Stocking, J. Schurr, P. Schwarzenberger, P. Oliver, W. Huang, P. Zhang, J. Zhang, J. E. Shellito, G. J. Bagby, S. Nelson, K. Charrier, J. J. Peschon, and J. K. Kolls. 2001. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J. Exp. Med. 194:519-527.